TraMag® Plus application successfully submitted to the URPL

We are proud to announce that on November 10, 2022, we successfully submitted an application to the URPL for market authorization of the medicinal product TraMag® Plus in Poland. At the same time on October 25 we received the expected response to our pre-IND submitted to the FDA in early 2022. These next milestones will allow us to further develop our plans for TraMag® Plus in EU and US.
Thanks to our Partners from SciencePharmaMEDICOFARMA S.A. Contract Manufacturer and Premier Consulting


linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram